Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder

Stock Information for Vistagen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vistagen Therapeutics Inc.

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen to Present at Stifel 2024 Virtual CNS Days
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.